PharmaCyte Biotech (PMCB) Profit After Tax (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Profit After Tax of -$4.4 million for Q2 2026, down 137.39% year-over-year from $11.7 million in Q2 2025, and down 688.26% quarter-over-quarter from $746860.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Profit After Tax (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Profit After Tax for 17 consecutive years, with -$4.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Profit After Tax fell 137.39% year-over-year to -$4.4 million; the TTM figure through Apr 2026 stood at -$19.4 million (down 163.36% YoY), while the FY2026 annual figure was -$19.4 million, down 163.36% from the prior year.
- Profit After Tax fell to -$4.4 million in Q2 2026 per PMCB's latest filing, from $746860.0 in the prior quarter.
- Across five years, Profit After Tax topped out at $23.4 million in Q3 2024 and bottomed at -$8.4 million in Q3 2025.
- Historically, Profit After Tax has averaged $278620.4 across 5 years, with a median of -$1.1 million in 2022.
- Annual changes were most pronounced in 2024 — Profit After Tax surged 1165.95% — and 2025, when it slumped 404.78%.
- PharmaCyte Biotech's Profit After Tax stood at -$1.9 million in 2022, then soared by 248.36% to $2.8 million in 2023, then tumbled by 152.67% to -$1.5 million in 2024, then plunged by 404.78% to -$7.4 million in 2025, then jumped by 40.77% to -$4.4 million in 2026.
- Business Quant data shows PMCB's Profit After Tax at -$4.4 million in Q2 2026, $746860.0 in Q1 2026, and -$7.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | -4.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -4.39 Mn |
| Jan 31, 2026 | 746,860.00 |
| Oct 31, 2025 | -7.42 Mn |
| Jul 31, 2025 | -8.36 Mn |
| Apr 30, 2025 | 11.75 Mn |
| Jan 31, 2025 | -3.05 Mn |
| Oct 31, 2024 | -1.47 Mn |
| Jul 31, 2024 | 23.42 Mn |
| Apr 30, 2024 | 1.35 Mn |
| Jan 31, 2024 | -619,537.00 |
| Oct 31, 2023 | 2.79 Mn |
| Jul 31, 2023 | -3.18 Mn |
| Apr 30, 2023 | -126,338.00 |
| Jan 31, 2023 | -764,136.00 |
| Oct 31, 2022 | -1.88 Mn |
| Jul 31, 2022 | -1.55 Mn |
| Apr 30, 2022 | -1.42 Mn |
| Jan 31, 2022 | -811,290.00 |
| Oct 31, 2021 | -979,746.00 |
| Jul 31, 2021 | -1.03 Mn |